New at CADTH — January 2019

News and Events

Save the date. The 2019 CADTH Symposium is being held in Edmonton, Alberta, from April 14 to 16, 2019. Applications for the CADTH Recognition Awards are open until January 14, 2019.

Drug Reimbursement Recommendations

CADTH recently issued the following CADTH Canadian Drug Expert Committee (CDEC) drug reimbursement recommendations:

• fluticasone propionate (Aermony RespiClick) for asthma
• fluticasone propionate / salmeterol xinafoate (Arbesda RespiClick) for asthma.

CADTH recently issued the following pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC) drug reimbursement recommendations:

• pertuzumab-trastuzumab (Perjeta-Herceptin) combo pack for the adjuvant treatment of HER2-positive early breast cancer patients at high risk of recurrence
• nivolumab (Opdivo) for the treatment of adult patients with advanced (not amenable to curative therapy or local therapeutic measures) or metastatic hepatocellular carcinoma who are intolerant to or have progressed on sorafenib therapy.

CADTH Reports

CADTH recently completed the following reports:

Rapid Response Reports — Drug

• Pharmacotherapy Management of Type 2 Diabetes Mellitus: Guidelines — Reference List
• Rapid Sequence Induction Agents for Emergency Intubation: Comparative Clinical Effectiveness and Guidelines — Reference List
• Blood Product Transfusions Prior to Surgical Interventions: Clinical Effectiveness and Guidelines — Summary of Abstracts

Rapid Response Reports — Medical Devices and Systems

• Treatment of Open Pneumothorax Prior to Chest Tube Insertion: Clinical Evidence and Guidelines — Reference List
• Pressure Offloading Cushions for Positioning Chairs: Clinical Evidence and Guidelines — Reference List
• N99 versus N100 Hepa Filters for Ventilator Circuits: Clinical Effectiveness, Safety and Evidence-based Guidelines — Reference List
• In-home Physical Post-Natal and Post-Partum Assessments: Clinical Effectiveness and Guidelines — Summary of Abstracts
• Halcyon Radiotherapy System for Patients Receiving Cancer Treatment: Clinical Effectiveness and Cost-Effectiveness — Summary of Abstracts
• Rehabilitation and Prevention of Hospital-Associated Deconditioning: Clinical Effectiveness and Guidelines — Summary of Abstracts
• Insulin Pumps for Patients with Any Diabetes Type: Clinical Effectiveness and Guidelines — Summary of Abstracts
• Continuous Glucose Monitoring for Patients with All Diabetes Types: Clinical Effectiveness and Guidelines — Summary of Abstracts
• Strategies for the Management of Latent or Previously Treated Tuberculosis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines — Summary of Abstracts
• Clinical Tests for Diagnosis of Scabies: Diagnostic Accuracy, Clinical Effectiveness, Cost Effectiveness, and Guidelines — Summary of Abstracts
• Social Worker Medical Visits for Outpatients with Diabetes in a Group Setting: Clinical Effectiveness, Cost-Effectiveness, and Guidelines — Summary of Abstracts
• Deep Brain Stimulation for Parkinson’s Disease: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines — Summary with Critical Appraisal
• Nociception Monitoring for General Anesthesia: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines — Summary with Critical Appraisal

Tools

• Publicly Funded and Managed Naloxone Programs in Canada
• Interventions for Insomnia Disorder

Tell Us What You Think

We love hearing how our products and services are influencing health care policies, clinical practices, and patient outcomes. If you have a success story to share, please get in touch with your CADTH Liaison Officer.

CADTH E-Alerts: Subscribe to receive the latest CADTH news, reports, feedback opportunities, and events.